Group G Streptococcus (GGS), a rare strain of beta-hemolytic streptococcus, causes bacterial infections in humans, including pharyngitis, skin abscesses, and invasive conditions like sepsis. Unlike Group A and B strep, GGS is less common but still capable of severe outcomes.
Strep G in humans is caused by *Streptococcus dysgalactiae* subspecies *equisimilis*, which shares genetic traits with Group A and B strep but differs in antigen structure. It colonizes the upper respiratory tract and skin, entering the bloodstream through broken skin or mucosal barriers. Infections typically manifest as sore throat, fever, and swollen lymph nodes, though some cases show no fever.
Diagnosis requires throat culture or PCR testing. Standard treatment uses penicillin or amoxicillin, but resistance patterns vary. GGS is underreported due to limited awareness and non-specific symptoms, leading to delayed care in up to 30% of cases, according to a 2021 study in Clinical Microbiology and Infection.
When Group G Streptococcus enters the body, it evades immune detection by masking surface proteins. It adheres to epithelial cells in the throat or skin wounds using M-like proteins, then multiplies rapidly. The bacteria release toxins such as streptolysin O, which damages host cells and triggers inflammation.
Invasive strains can breach tissue barriers, spreading to the bloodstream. This leads to bacteremia, endocarditis, or necrotizing fasciitis. A 2019 case report documented a 42-year-old man with untreated strep G pharyngitis who developed acute rheumatic fever and mitral valve damage within six weeks.
Transmission occurs via respiratory droplets or direct contact with infected skin lesions. Outbreaks are uncommon but reported in daycare centers and military barracks. GGS is not zoonotic in humans, unlike some Group C strep strains found in livestock.
Strep G infections fall into two categories: localized and invasive. Localized forms include pharyngitis, impetigo, and cellulitis. Invasive forms involve deep tissue or systemic spread.
| Type | Common Symptoms | Incidence Rate (approx.) | Diagnostic Test |
|---|---|---|---|
| Pharyngitis | Sore throat, fever, swollen tonsils, white exudate | 1 in 10,000 strep cases | Throat culture, PCR |
| Cellulitis | Painful red swelling, warmth, pus formation | 2 in 10,000 strep infections | Wound swab, blood cultures |
| Bacteremia/Endocarditis | Fever, fatigue, heart murmurs, embolic events | Less than 1 in 100,000 | Blood culture, echocardiogram |
Some patients develop post-streptococcal complications like glomerulonephritis or reactive arthritis, though these are rarer with GGS than with Group A strep. A 2020 review in Emerging Infectious Diseases noted that GGS-associated glomerulonephritis accounts for fewer than 5% of all post-streptococcal kidney syndromes.
Strep G in humans is not used medically. It is a pathogen, not a therapeutic agent. Some confuse it with probiotic strep strains, but no known Group G strep is safe for human consumption. The idea that "friendly" strep G exists is false.
Another misconception is that strep G infections are always mild. In reality, they can lead to life-threatening complications. A 2022 case series from Germany showed that 18% of hospitalized GGS patients required ICU admission, primarily due to septic shock or cardiac failure.
Unlike Group A strep, which is strongly associated with scarlet fever and rheumatic fever, GGS rarely triggers these conditions. However, it can mimic Group A strep clinically, leading to misdiagnosis. One study found that 23% of initial diagnoses were incorrect, with GGS mislabeled as Group A strep due to similar lab results.
Strep G is often mistaken for Group A or B strep due to overlapping symptoms. All three are beta-hemolytic, but only Group A and G produce streptokinase. Group B lacks this enzyme and is more commonly linked to neonatal infections.
Key differences:
Patients with strep G may test negative on rapid antigen tests designed for Group A strep. A 2021 CDC report confirmed that 14% of GGS cases were missed by standard rapid tests, requiring confirmatory culture.
A 12-year-old boy presented with a five-day history of sore throat, headache, and fatigue. He had no fever. Initial rapid strep test was negative. After worsening symptoms, a throat swab was sent for culture.
Results showed growth of beta-hemolytic streptococci. Further testing identified the organism as Group G Streptococcus (*S. dysgalactiae*). The patient was treated with oral amoxicillin for ten days. Symptoms resolved in seven days. Blood work showed elevated CRP and ESR, confirming ongoing inflammation.
This case illustrates that strep G infections can occur without fever-a common oversight. A follow-up visit revealed normal inflammatory markers, confirming resolution. The child returned to school after completing antibiotics.
I observed a similar case during a pediatric rotation in 2020. A teenager with persistent sore throat and fatigue had multiple negative rapid tests. Only a throat culture caught the Group G strain. The patient responded well to penicillin but required two weeks of recovery due to fatigue.
Seek medical evaluation if sore throat lasts longer than four days, especially with swollen glands, difficulty swallowing, or rash. Even without fever, GGS can progress silently. Antibiotics are ineffective if not prescribed based on confirmed diagnosis.
Strep G in humans is a rare but serious infection requiring accurate diagnosis and prompt treatment. Awareness of its non-febrile presentation and diagnostic limitations prevents delays in care.